209 related articles for article (PubMed ID: 26824047)
1. Type 2 Diabetes and ADP Receptor Blocker Therapy.
Samoš M; Fedor M; Kovář F; Mokáň M; Bolek T; Galajda P; Kubisz P; Mokáň M
J Diabetes Res; 2016; 2016():6760710. PubMed ID: 26824047
[TBL] [Abstract][Full Text] [Related]
2. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
3. Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics.
Hernandez-Suarez DF; Scott SA; Tomey MI; Melin K; Lopez-Candales A; Buckley CE; Duconge J
Ther Adv Cardiovasc Dis; 2017 Sep; 11(9):235-241. PubMed ID: 28675986
[TBL] [Abstract][Full Text] [Related]
4. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
Bertling A; Fender AC; Schüngel L; Rumpf M; Mergemeier K; Geißler G; Sibrowski W; Kelsch R; Waltenberger J; Jakubowski JA; Kehrel BE
J Thromb Haemost; 2018 Jun; 16(6):1089-1098. PubMed ID: 29582544
[TBL] [Abstract][Full Text] [Related]
5. Randomized Comparison of Oral P2Y
Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
[TBL] [Abstract][Full Text] [Related]
6. Response variability to P2Y12 receptor inhibitors: expectations and reality.
Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
[TBL] [Abstract][Full Text] [Related]
7. Clinical use of clopidogrel.
Sarafoff N; Byrne RA; Sibbing D
Curr Pharm Des; 2012; 18(33):5224-39. PubMed ID: 22724411
[TBL] [Abstract][Full Text] [Related]
8. New anti-platelet agents: the end of resistance?
Kastrati A
Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663
[TBL] [Abstract][Full Text] [Related]
9. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
[TBL] [Abstract][Full Text] [Related]
10. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?
Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
Thromb Haemost; 2015 Jan; 113(1):37-52. PubMed ID: 25231675
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients.
Alexopoulos D; Xanthopoulou I; Davlouros P; Tsigkas G; Damelou A; Theodoropoulos KC; Gkizas V; Hahalis G
J Thromb Haemost; 2013 Feb; 11(2):381-4. PubMed ID: 23216658
[No Abstract] [Full Text] [Related]
12. Antiplatelet therapy. Cangrelor succeeds, at last, in PCI.
Storey RF
Nat Rev Cardiol; 2013 Jun; 10(6):302-4. PubMed ID: 23609175
[No Abstract] [Full Text] [Related]
13. Development and clinical use of prasugrel and ticagrelor.
Ahmad S; Storey RF
Curr Pharm Des; 2012; 18(33):5240-60. PubMed ID: 22724412
[TBL] [Abstract][Full Text] [Related]
14. Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor-a long continuing journey.
Kaul U; Mansoor AH
Indian Heart J; 2012; 64(1):54-9. PubMed ID: 22572427
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
Máchal J; Hlinomaz O
Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
[TBL] [Abstract][Full Text] [Related]
16. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: systematic review and meta-analyses of randomized clinical trials.
Zaccardi F; Pitocco D; Willeit P; Laukkanen JA
Atherosclerosis; 2015 Jun; 240(2):439-45. PubMed ID: 25897998
[TBL] [Abstract][Full Text] [Related]
18. Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays.
Consuegra-Sánchez L; López-Palop R; Cano P; Carrillo P; Picó F; Villegas M; Sanchis J; Kaski JC
J Thromb Haemost; 2013 Feb; 11(2):379-81. PubMed ID: 23253198
[No Abstract] [Full Text] [Related]
19. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Westman PC; Lipinski MJ; Torguson R; Waksman R
Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
[TBL] [Abstract][Full Text] [Related]
20. Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis.
Wen M; Li Y; Qu X; Zhu Y; Tian L; Shen Z; Yang X; Shi X
BMC Cardiovasc Disord; 2020 Oct; 20(1):430. PubMed ID: 33004000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
